Author Interviews, Hematology, Pediatrics / 08.12.2025
Nemours Study Evaluates fitusiran for Bleeding Prophylaxis During Minor Surgery in hemophilia A
[caption id="attachment_71709" align="alignleft" width="202"] Dr. Zorrilla[/caption]
MedicalResearch.com Interview with:
Julian Zorrilla, DO
Pediatric Hematologist/Oncologist
Nemours Children’s Health
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Non-factor therapies are a novel treatment approach for people with hemophilia A and B with and without inhibitors.
Fitusiran is a first-of-its-kind “rebalancing” agent that provides effective hemostatic control from bleeds in people with hemophilia. This study describes the experience of people with hemophilia who are on fitusiran in regard to minor surgeries. This data shows minor surgeries can be effectively and safely performed for those patients who are on fitusiran for their prophylaxis. A subset of individuals on fitusiran did not require any other medications to help prevent surgical bleeding.
Dr. Zorrilla[/caption]
MedicalResearch.com Interview with:
Julian Zorrilla, DO
Pediatric Hematologist/Oncologist
Nemours Children’s Health
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Non-factor therapies are a novel treatment approach for people with hemophilia A and B with and without inhibitors.
Fitusiran is a first-of-its-kind “rebalancing” agent that provides effective hemostatic control from bleeds in people with hemophilia. This study describes the experience of people with hemophilia who are on fitusiran in regard to minor surgeries. This data shows minor surgeries can be effectively and safely performed for those patients who are on fitusiran for their prophylaxis. A subset of individuals on fitusiran did not require any other medications to help prevent surgical bleeding.